Clinical trial

Single Dose Versus Double Dose Tamsulosin in Management of Moderate and Severe Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

Name

SD vs DD Tamsulosin

Description

Single dose versus double dose tamsulosin in Management of Moderate and severe lower urinary tract symptoms due to benign prostatic hyperplasia

Trial arms

Trial start

2022-05-01

Estimated PCD

2022-12-01

Trial end

2022-12-01

Status

Completed

Treatment

Single dose tamsulosin 0.4mg

Arms:

Single dose tamsulosin 0.4mg

Double dose tamsulosin 0.4mg

Arms:

Double dose tamsulosin 0.4mg

Size

Primary endpoint

Change in the lower urinary tract symptoms

3 months

Eligibility criteria

Inclusion Criteria: * age more than 50 years * moderate to severe lower urinary tract symptoms Exclusion Criteria: * prostatic cancer * urethral stricture * prostate surgery * Neurogenic bladder

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER']}}, 'enrollmentInfo': {'count': 60, 'type': 'ACTUAL'}}

Updated at

2023-04-28

1 organization

1 product

4 indications

Organization

Product

Indication

Indication

Indication

Lower Urinary Tract Symptoms

Indication

Prostate Hypertrophy